|
|
 |
|
Viewing report
|
|
|
|
Antisense cancer therapies
Datamonitor, March 2002
The development of antisense compounds will provide physicians with a highly efficacious family of compounds exhibiting favorable side-effect profiles. Within this class, Genta''s Genasense is predicted to be the key compound. The development of antisense therapeutics provides a rapid discovery-to-laboratory time frame that would suit the limited cash resources of the biotechnology sector and provides substantial innovative pipeline-building potential. However, the success of this class of compounds is largely dependent on the level of skepticism the physicians and the pharmaceutical industry holds upon the initial product launches, and how well they individually perform in the clinic. This report discusses the rise of the antisense therapeutic in cancer, and the skepticism surrounding the class’ history, whereby a successful product launch has the potential to create a new wave of therapy evolution.
Customers who bought this item also bought
Immunotherapy in Oncology: Gaining Momentum
Triple Progress Analysis - Melanoma, Colorectal & Lung Cancer
Stakeholder Insight: Hormonal Therapies in Breast Cancer
Drug Delivery in Cancer - Technologies, Markets and Companies
Targeted Cancer Therapies: Innovative Drugs And Their Impact On The Future Of Oncology
Analytical Tool - Current & Future Therapies for Colorectal Cancer
Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
Stakeholder Insight: Adjunct Therapies in Breast Cancer
|
|
|
|
